TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01379300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
Study: NCT00651365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877605
Study: NCT01403116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Description: Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical testosterone gel
Description: Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
Study: NCT00985088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: one or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: one or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: one or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: one or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: one or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: one or two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: One injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: One injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: One injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: One injection
Study: NCT03125148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enteral stenting
Description: Enteral stent for malignant duodenal obstruction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enteral stenting
Description: Enteral stent for malignant duodenal obstruction
Study: NCT02016365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: 750 mg/day (500 mg +250mg orally) continuously
Study: NCT03730038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of pitavastatin 4 mg qd for 12 weeks
Description: Treatment of pitavastatin 4 mg qd for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification
Description: Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
Study: NCT01491815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-biological DMARD's
Description: Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
Study: NCT03134339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine saline 0.00mcg/kg/s
Description: saline 0.00mcg/kg/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.24 mcg/kg/s
Description: nicotine 0.24 mcg/kg/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.048 mcg/kg/s
Description: nicotine 0.048 mcg/kg/s

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine 0.024 mcg/kg/s
Description: nicotine 0.024 mcg/kg/s
Study: NCT03853564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Feedback Intervention
Description: Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
Study: NCT02683421

Intervention type: DRUG
Group type: OTHER
Intervention: Tilmanocept

Intervention type: DRUG
Group type: OTHER
Intervention: Tilmanocept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilmanocept
Study: NCT01358747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEACOPPesc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPPesc - ABVD - PET2
Study: NCT03167268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01778634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin intravenous 20 mg/kg every 24 h x 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5W
Study: NCT01491815

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cimzia
Description: Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
Study: NCT04196881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge Improvement Program about ADHD
Description: This training program will cover an overview of ADHD, prevalence, causes, symptoms, risk factors, associated impairment, prognosis, and treatment options including behavioral interventions and medication.
Study: NCT04277962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triton L and D system for estimation of blood loss at time of vaginal delivery
Description: The Triton L\&D system (Gauss Surgical, Inc., Menlo Park, CA) is an FDA-cleared mobile application on a tablet computer (iPad) that facilitates quantification of blood loss (QBL) by providing an easy to use process and user interface. Dry weights of all potential blood containing substrates are built-in to the device allowing batch weighing with automatic subtraction of dry weights. There is also a V-drape simulator accounting for collected fluids with automatic subtraction of a measured amount of amniotic fluid.
Study: NCT03156504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
Study: NCT01783912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive / Motivational Individual Sessions
Description: Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Individual Sessions
Description: Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Curriculum
Description: Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Curriculum
Description: Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
Study: NCT03600987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous music and reading lyrics
Description: listening to music with singing of the lyrics simultaneously with reading the written lyrics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming with music
Description: priming by listening to music and singing of the lyrics followed by reading the written lyrics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: control condition using reading materials without music.
Study: NCT04315506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #EnufSnuff.TXT Intervention
Description: The SGR program will reduce smokeless tobacco until you reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enough Snuff Intervention
Description: Participants will be sent the Enough Snuff cessation manual. One weeks after it is sent, participants will then receive text messages from the study team twice a week for ten weeks.
Study: NCT04902014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The individuals will be scheduled for and participate in six biweekly in person SDT based MI sessions. These sessions will take place in the HPCRL at CSU. The MI sessions will be conducted by a PhD student who has been trained by a MI practitioner. Participants will be provided a log book and will be asked to log their PA, with the goal of completing at least 150 minutes of PA per week. They will set biweekly PA goals, which will be discussed in the MI sessions. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: These participants will receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting. These participants will not do any other study related activities. At the conclusion of the study, these participants will be offered the chance to participate in one MI session.
Study: NCT01491815

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Orencia
Description: Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RoActemra
Description: Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week
Study: NCT00913055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Description: subcutaneous implant
Study: NCT04902014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable Fitness Trackers
Description: Individuals assigned to this experimental condition will be given a wrist-worn WFT and will be instructed to wear it for the duration of the study. They will also download the corresponding mobile application on their smartphones. They will be trained by a member of our team on how to utilize the WFT and mobile application. The intended WFT tracks daily steps, miles traveled, kcals expended, and daily activity time. This device provides these data to the wearer via a small screen. Participants will be instructed to aim to complete at least 150 minutes of PA per week. Researchers will have the capability to track participant daily PA via the WFT and associated API. These individuals will be asked to set biweekly PA goals. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
Study: NCT05671549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis of the temporomandibular joint
Description: Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis of the temporomandibular joint
Description: Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
Study: NCT04527965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Customized diet to reduce liver fat
Description: Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet
Description: Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided
Study: NCT03853564

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Phone-Call Intervention
Description: Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
Study: NCT03001778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usability Testing
Description: Usability testing of ready made workouts in a group format.
Study: NCT04902014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable Fitness Tracker+
Description: These individuals will be given the wrist-worn WFT, be instructed to wear it for the duration of the study AND be scheduled for six SDT based MI sessions. These participants will also be trained by a member of our team on how to utilize the WFT and associated application. They will be instructed to aim to complete 150 minutes of PA per week. These participants will be asked to set biweekly PA goals which will be discussed in MI sessions. Researchers will have the capability to track participant daily PA via the WFT and associated API. These participants will also receive general physical activity guidelines education and information on strategies to reach the recommended amount of activity per week during the initial baseline assessment meeting.
Study: NCT02614105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: 16 weeks of group-based exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough-suppression therapy
Description: Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Brief information only
Study: NCT01942772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle-Foot Orthosis
Study: NCT03946631

Intervention type: DIAGNOSTIC_TEST
Intervention: 2 hour glucose tolerance test using 75g glucose drink
Description: intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
Study: NCT04613947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed consent
Description: The style of informing patients about the procedure they will undergo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informed consent
Description: The style of informing patients about the procedure they will undergo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed consent
Description: The style of informing patients about the procedure they will undergo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed consent
Description: The style of informing patients about the procedure they will undergo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third molar surgery
Description: Surgical extraction of the third molar tooth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Third molar surgery
Description: Surgical extraction of the third molar tooth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third molar surgery
Description: Surgical extraction of the third molar tooth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Third molar surgery
Description: Surgical extraction of the third molar tooth
Study: NCT04316494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate
Study: NCT03941366

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care chemotherapy with the change for avoidance of extensive surgery
Description: All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
Study: NCT02304445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE+Stereotactic Body Radiotherapy
Description: This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
Study: NCT02216994

Intervention type: DRUG
Group type: OTHER
Intervention: high dose lactulose
Description: The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conservative treatment
Description: The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.

Intervention type: DRUG
Group type: OTHER
Intervention: paraffin oil
Description: The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
Study: NCT03742297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide.
Description: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide.
Description: Lenalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide.
Description: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan
Study: NCT01722097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04466735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active group
Description: 2 x 12 g of EKS/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active group
Description: 2 x 12 g of EKS/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Isocaloric placebo supplement with similar salt load but no EKS